About SepThera
We are pioneering the future of sepsis treatment through innovative extracorporeal therapy technology.
Our Mission
To revolutionize sepsis treatment by developing innovative extracorporeal therapies that selectively remove harmful immune mediators while preserving beneficial immune components, ultimately saving lives and reducing healthcare costs.
Our Technology
SepThera's proprietary reverse-dialysis technology represents a breakthrough in sepsis treatment, offering a targeted approach to address the inflammatory cascade that drives sepsis progression.
Selective Filtration
Our technology selectively removes harmful cytokines and inflammatory mediators while preserving beneficial immune components.
Patent Protected
Our proprietary reverse-dialysis process is protected by comprehensive intellectual property rights.
Clinical Focus
Designed for integration into existing hospital infrastructure with a clear pathway to clinical implementation.
Our Values
We are driven by a commitment to innovation, patient care, and scientific excellence in everything we do.
Innovation
Pushing the boundaries of medical technology to create breakthrough treatments.
Patient Focus
Every decision we make is guided by our commitment to improving patient outcomes.
Scientific Rigor
Maintaining the highest standards of scientific and clinical excellence.
Integrity
Operating with transparency, honesty, and ethical responsibility in all our endeavors.
Our Leadership Team
Founded by Dr. Mitchell S. Felder and supported by world-renowned experts in neurology, regenerative medicine, oncology, and artificial intelligence.
Dr. Mitchell S. Felder
Founder
Board-certified neurologist, prolific inventor, and biotech innovator with over four decades of experience. Holds 21 issued patents centered on pioneering extracorporeal treatment platforms designed to physically remove disease-causing agents from the bloodstream.
"The future of medicine lies in physically removing the pathophysiologic basis of disease."
Dr. Oliver Zolman
Technical Advisor
Cambridge-based medical doctor specializing in evidence-based longevity and regenerative medicine. Graduate of King's College London with First Class Honours in Regenerative Medicine and expertise in clinical trial design.
"SepThera's approach represents a paradigm shift in how we address inflammatory conditions."
Dr. Patrick Sewell Jr.
Technical Advisor
Pioneering physician-scientist with over three decades of experience in interventional oncology, gene therapy, and regenerative medicine. Expert in minimally invasive, image-guided therapies and gene transfer protocols.
"The selective filtration technology developed by SepThera has applications beyond sepsis that could transform multiple fields of medicine."
Carrie Criado, Esq.
Legal Counsel
Seasoned communications strategist, attorney, and educator with a distinguished career spanning journalism, law, and higher education. Holds a Juris Doctor from the University of Houston Law Center.
"Our robust intellectual property strategy ensures SepThera's innovations are well-protected as we advance our mission."
Julian Trajanson
Technical Advisor
Machine learning engineer and AI innovator with over eight years of experience developing intelligent systems. Wharton School alumnus specializing in the integration of advanced AI methodologies to enhance SepThera's precision filtration platform.
"By integrating AI with SepThera's filtration technology, we're creating smarter, more responsive treatment protocols that adapt to individual patient needs."
Schedule a Consultation with Dr. Felder
Discuss SepThera's innovative sepsis treatment technology and explore potential partnerships
What to Expect
- Deep dive into SepThera's proprietary technology
- Discussion of clinical applications and potential
- Exploration of partnership opportunities
- Q&A with our founder and lead scientist
Ideal for:
Schedule a Meeting with Dr. Felder
Book a consultation to discuss SepThera's innovative sepsis treatment technology
Transforming Sepsis Care Worldwide
SepThera is dedicated to revolutionizing sepsis treatment through our proprietary reverse-dialysis technology. Our mission is to significantly reduce sepsis mortality rates and improve patient outcomes by addressing the root cause of sepsis progression.
"The Felder Doctrine: physically removing the pathophysiologic basis of disease."
— Dr. Mitchell S. Felder, Founder
Founded by Dr. Mitchell S. Felder, SepThera builds on decades of research and innovation in extracorporeal treatment platforms designed to physically remove disease-causing agents from the bloodstream.
- Develop innovative therapies for sepsis and related conditions
- Advance clinical research in extracorporeal treatment technologies
- Partner with leading medical institutions to improve patient care
- Reduce the global burden of sepsis through accessible treatment options
Our technology targets the inflammatory mediators that drive sepsis progression.
Our Core Values
The principles that guide our work and define our approach to innovation in healthcare.
Patient-Centered Innovation
We place patients at the center of everything we do, developing technologies that address critical unmet needs and improve outcomes.
Scientific Excellence
We maintain the highest standards of scientific rigor in our research, development, and clinical validation processes.
Collaborative Innovation
We foster partnerships with leading medical institutions, researchers, and clinicians to accelerate the development of life-saving technologies.
Expert Perspectives
Insights from leading medical professionals on SepThera's innovative approach to sepsis treatment.
SepThera's approach to sepsis treatment represents a paradigm shift in how we think about managing this deadly condition. By directly addressing the inflammatory cascade, they're tackling sepsis at its core.
Dr. Sarah Reynolds
Chief of Critical Care, Boston Memorial Hospital
The extracorporeal filtration technology developed by SepThera shows tremendous promise. Their selective approach to removing inflammatory mediators while preserving beneficial immune components is truly innovative.
Professor James Chen
Director, Institute for Immunology Research
Join Our Mission
Whether you're an investor, researcher, clinician, or potential team member, we invite you to be part of our journey to transform sepsis care.